Skip to content
Jean M. Bidlack, Ph.D.

Jean M. Bidlack, Ph.D.

Research Lab

About Me

Faculty Appointments

Professor - Department of Pharmacology and Physiology (SMD)

Associate Chair - Department of Pharmacology and Physiology (SMD)

Credentials

Education

PhD | Univ Rochester Sch Med/Dent. Biophysics. 1979

MS | Univ Rochester Sch Med/Dent. Biophysics. 1977

BA | Skidmore College. Biology - Chemistry. 1975

Awards

College of CSR Reviewers. 2010

Excellence in Research Award. 2007

University Dean's Award for Meritorious Service in Ph.D. Defenses. 2007

Distinguished Service Award. 2005

Periclean Alumna Scholar Award. 2004

The Alumni Award for Excellence in Graduate Education. 2001

NIH Senior Scientist Award. 1998 - 2008

Wallace O. Fenn Mentor Award. 1995

Periclean Scholar Award. 1975

Research

Discovery of Samidorphan, a medication currently in multiple Phase 2 and Phase 3 clinical trials:

In collaboration with Dr. Mark P. Wentland at Rensselaer Polytechnic Institute, the main goal of our research is to design, synthesize and characterize oral, long-acting modulators of opioid G pr...
Discovery of Samidorphan, a medication currently in multiple Phase 2 and Phase 3 clinical trials:

In collaboration with Dr. Mark P. Wentland at Rensselaer Polytechnic Institute, the main goal of our research is to design, synthesize and characterize oral, long-acting modulators of opioid G protein-coupled receptors (GPCRs) as medications to treat cocaine abuse and other central nervous system disorders in humans. A common structural feature of the large majority of opioids is a phenolic-OH group (see prototypic opioid structure below) that plays a crucial role in molecular recognition via H-bonding to a histidine residue of an opioid GPCR. For many opioids, however, this OH group is responsible for poor oral bioavailability and/or short half-life via O-glucuronidation. In 2001, we published the first report that a carboxamide group (CONH2) was an effective replacement for this prototypic phenolic-OH group of opioids. In addition to high affinity binding to opioid GPCRs, certain carboxamido-substituted opioids have much improved pharmacokinetic properties (relative to their phenolic-OH counterparts) as a consequence of high metabolic stability.

Since 2001, our research group has focused on capitalizing on this discovery to achieve our main goal. Our first-generation opioid modulator in this series was 8-carboxamidocyclazocine (8-CAC) and a next generation agent is samidorphan (formerly referred to as ALKS 33). 8-CAC produced analgesia in mice for 16 hours in comparison to morphine which produces analgesia for less than 2 hours. Our publications describing these discoveries as well as a wealth of structure-activity relationship data are catalogued in the PubMed link found below.

In September 2006, Rensselaer signed a license agreement granting Alkermes Inc. - a biotechnology company now based in Ireland - exclusive rights to a library of opioid compounds discovered by our team. The Bidlack lab continues to work with Alkermes to discover new opioids that may be pharmacotherapeutics. Alkermes recently announced the initiation of multiple phase 3 clinical studies of ALKS 5461 (samidorphan in combination with buprenorphine) for treatment of patients with major depressive disorder. The U.S. Food and Drug Administration (FDA) has granted Fast Track status for ALKS 5461. Alkermes also announced the initiation of multiple phase 2 clinical studies of ALKS 3831, a novel oral atypical antipsychotic drug candidate designed to be a broad spectrum treatment for schizophrenia. ALKS 3831 is composed of samidorphan in combination with the established antipsychotic drug, olanzapine. See the following press releases from Alkermes for details:

Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461 for Treatment of Major Depressive Disorder

Alkermes Announces Initiation of ALKS 5461 Pivotal Clinical Program for Treatment of Major Depressive Disorder

Alkermes Receives Fast Track Designation for ALKS 5461 for Major Depressive Disorder

Alkermes Announces Initiation of Second Phase 2 Clinical Study of ALKS 3831, a Novel Broad-Spectrum Oral Antipsychotic

Alkermes Announces Initiation of Phase 2 Clinical Study of ALKS 3831, Designed to Be a Broad Spectrum Oral Antipsychotic for the Treatment of Schizophrenia

Patents

N-Substituted Derivatives of Morphinan and Uses Thereof

Issue date: January 18, 2005

Patent #: 6,844,438

Country: United States

Inventors: Jean M Bidlack, Xia-Hui Gu, John L Neumeyer

Treatment of Cocaine Abuse Using N-Substituted Derivatives of Morphinan

Issue date: November 06, 2007

Patent #: 7,291,628

Country: United States

Inventors: Jean M Bidlack, Xia-Hui Gu, John L Neumeyer

Compositions and Methods for Inhibiting G Protein Signaling

Issue date: March 10, 2015

Patent #: 8,975,259

Country: United States

Inventors: Jean M Bidlack, Burns C Blaxall, Alan V Smrcka

Publications

Journal Articles

The 27th Scientific Conference of the Society on NeuroImmune Pharmacology: New Delhi, India, March 15-18, 2023.

Chang SL, Seth P, Zhu J, Pendyala G, Bidlack JM, Kumar S

NeuroImmune pharmacology and therapeutics.. 2023 June 2 (2):187-244. Epub 04/10/2023.

The Neuroimmune Pharmacology of SARS-CoV-2.

Kumar S, Yelamanchili S, Seth P, Bidlack JM, Pendyala G, Maggirwar S, Chang SL

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.. 2021 December 22 Epub 12/22/2021.

The COVID-19 Pandemic: Reflections of Science, Person, and Challenge in Academic Research Settings.

Bidlack JM, Chang SL, Fitting S, Gendelman HE, Gorantla S, Kumar S, Marcondes MCG, Meigs DD, Melendez LM, Sariyer IK, Yelamanchili S

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.. 2021 November 26 Epub 11/26/2021.

Mice with high FGF21 serum levels had a reduced preference for morphine and an attenuated development of acute antinociceptive tolerance and physical dependence.

Dorval L, Knapp BI, Majekodunmi OA, Eliseeva S, Bidlack JM

Neuropharmacology.. 2021 October 26202 :108858. Epub 10/26/2021.

Society on NeuroImmune Pharmacology COVID-19 Virtual Workshop.

Kumar S, Pendyala G, Yelamanchili SV, Seth P, Maggirwar S, Bidlack JM, Chang SL

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.. 2021 June 28 Epub 06/28/2021.

The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia.

Bartlett MJ, Mabrouk OS, Szabò L, Flores AJ, Parent KL, Bidlack JM, Heien ML, Kennedy RT, Polt R, Sherman SJ, Falk T

International journal of molecular sciences.. 2020 December 2222 (1)Epub 12/22/2020.

Unique Pharmacological Properties of the Kappa Opioid Receptor Signaling Through Gz as Shown with Bioluminescence Resonance Energy Tranfer.

Barnett ME, Knapp BI, Bidlack JM

Molecular pharmacology.. 2020 October 98 (4):462-474. Epub 07/27/2020.

Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration.

Stevenson GW, Giuvelis D, Cormier J, Cone K, Atherton P, Krivitsky R, Warner E, St Laurent B, Dutra J, Bidlack JM, Szabò L, Polt R, Bilsky EJ

Psychopharmacology.. 2020 January 7 Epub 01/07/2020.

Author Correction: Noradrenergic signaling in the wakeful state inhibits microglial surveillance and synaptic plasticity in the mouse visual cortex.

Stowell RD, Sipe GO, Dawes RP, Batchelor HN, Lordy KA, Whitelaw BS, Stoessel MB, Bidlack JM, Brown E, Sur M, Majewska AK

Nature neuroscience.. 2020 January 23 (1):152. Epub 1900 01 01.

Noradrenergic signaling in the wakeful state inhibits microglial surveillance and synaptic plasticity in the mouse visual cortex.

Stowell RD, Sipe GO, Dawes RP, Batchelor HN, Lordy KA, Whitelaw BS, Stoessel MB, Bidlack JM, Brown E, Sur M, Majewska AK

Nature neuroscience.. 2019 October 21 Epub 10/21/2019.

In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder.

Bidlack JM, Knapp BI, Deaver DR, Plotnikava M, Arnelle D, Wonsey AM, Toh MF, Pin SS, Namchuk MN

The Journal of pharmacology and experimental therapeutics.. 2018 November 367 (2):267-281. Epub 08/14/2018.

Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-?-induced depression model.

Callaghan CK, Rouine J, Dean RL, Knapp BI, Bidlack JM, Deaver DR, O'Mara SM

Brain, behavior, and immunity.. 2018 January 67 :152-162. Epub 08/24/2017.

Structural Requirements for CNS Active Opioid Glycopeptides.

Lefever M, Li Y, Anglin B, Muthu D, Giuvelis D, Lowery JJ, Knapp BI, Bidlack JM, Bilsky EJ, Polt R

Journal of medicinal chemistry.. 2015 August 1358 (15):5728-41. Epub 07/23/2015.

Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to ?-endorphin?

Li Y, St Louis L, Knapp BI, Muthu D, Anglin B, Giuvelis D, Bidlack JM, Bilsky EJ, Polt R

Journal of medicinal chemistry.. 2014 March 2757 (6):2237-46. Epub 03/07/2014.

Preliminary pharmacological evaluation of enantiomeric morphinans.

Sromek AW, Provencher BA, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL

ACS chemical neuroscience.. 2014 February 195 (2):93-9. Epub 01/08/2014.

Mixed ?/? partial opioid agonists as potential treatments for cocaine dependence.

Bidlack JM

Advances in pharmacology.. 2014 69 :387-418. Epub 1900 01 01.

Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.

Provencher BA, Sromek AW, Li W, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL

Journal of medicinal chemistry.. 2013 November 1456 (21):8872-8. Epub 10/29/2013.

Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 9: Synthesis, characterization and molecular modeling of pyridinyl isosteres of N-BPE-8-CAC (1), a high affinity ligand for opioid receptors.

Vanalstine MA, Wentland MP, Alvarez J, Cao Q, Cohen DJ, Knapp BI, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2013 April 123 (7):2128-33. Epub 02/08/2013.

Inhibition of G??-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward.

Hoot MR, Sypek EI, Reilley KJ, Carey AN, Bidlack JM, McLaughlin JP

Behavioural pharmacology.. 2013 April 24 (2):144-52. Epub 1900 01 01.

Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC.

Wentland MP, Jo S, Gargano JM, Vanalstine MA, Cohen DJ, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2012 December 1522 (24):7340-4. Epub 10/27/2012.

Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.

Neumeyer JL, Zhang B, Zhang T, Sromek AW, Knapp BI, Cohen DJ, Bidlack JM

Journal of medicinal chemistry.. 2012 April 2655 (8):3878-90. Epub 04/04/2012.

Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins.

Li Y, Lefever MR, Muthu D, Bidlack JM, Bilsky EJ, Polt R

Future medicinal chemistry.. 2012 February 4 (2):205-26. Epub 1900 01 01.

Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats.

Dean RL, Eyerman D, Todtenkopf MS, Turncliff RZ, Bidlack JM, Deaver DR

Pharmacology, biochemistry, and behavior.. 2012 January 100 (3):530-7. Epub 10/25/2011.

Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environments.

Yeomans L, Muthu D, Lowery JJ, Martinez HN, Abrell L, Lin G, Strom K, Knapp BI, Bidlack JM, Bilsky EJ, Polt R

Chemical biology & drug design.. 2011 November 78 (5):749-56. Epub 09/26/2011.

Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for ?, ?, and ? opioid receptors.

Zhang B, Zhang T, Sromek AW, Scrimale T, Bidlack JM, Neumeyer JL

Bioorganic & medicinal chemistry.. 2011 May 119 (9):2808-16. Epub 03/26/2011.

Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic.

Hough LB, Nalwalk JW, Yang J, Conroy JL, VanAlstine MA, Yang W, Gargano J, Shan Z, Zhang SZ, Wentland MP, Phillips JG, Knapp BI, Bidlack JM, Zuiderveld OP, Leurs R, Ding X

Pain.. 2011 April 152 (4):878-87. Epub 1900 01 01.

Aminothiazolomorphinans with mixed ? and ? opioid activity.

Zhang T, Yan Z, Sromek A, Knapp BI, Scrimale T, Bidlack JM, Neumeyer JL

Journal of medicinal chemistry.. 2011 March 2454 (6):1903-13. Epub 02/25/2011.

In vivo characterization of MMP-2200, a mixed ?/? opioid agonist, in mice.

Lowery JJ, Raymond TJ, Giuvelis D, Bidlack JM, Polt R, Bilsky EJ

The Journal of pharmacology and experimental therapeutics.. 2011 March 336 (3):767-78. Epub 11/30/2010.

Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic.

Balboni G, Salvadori S, Marczak ED, Knapp BI, Bidlack JM, Lazarus LH, Peng X, Si YG, Neumeyer JL

European journal of medicinal chemistry.. 2011 February 46 (2):799-803. Epub 12/08/2010.

Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.

Fulton BS, Knapp BL, Bidlack JM, Neumeyer JL

Bioorganic & medicinal chemistry letters.. 2010 March 120 (5):1507-9. Epub 01/25/2010.

Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling.

Conroy JL, Fang C, Gu J, Zeitlin SO, Yang W, Yang J, VanAlstine MA, Nalwalk JW, Albrecht PJ, Mazurkiewicz JE, Snyder-Keller A, Shan Z, Zhang SZ, Wentland MP, Behr M, Knapp BI, Bidlack JM, Zuiderveld OP, Leurs R, Ding X, Hough LB

Nature neuroscience.. 2010 March 13 (3):284-6. Epub 02/07/2010.

Evolution of the Bifunctional Lead ? Agonist / ? Antagonist Containing the Dmt-Tic Opioid Pharmacophore.

Balboni G, Salvadori S, Trapella C, Knapp BI, Bidlack JM, Lazarus LH, Peng X, Neumeyer JL

ACS chemical neuroscience.. 2010 February 171 (2):155-164. Epub 1900 01 01.

Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.

Decker M, Si YG, Knapp BI, Bidlack JM, Neumeyer JL

Journal of medicinal chemistry.. 2010 January 1453 (1):402-18. Epub 1900 01 01.

Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.

Decker M, Fulton BS, Zhang B, Knapp BI, Bidlack JM, Neumeyer JL

Journal of medicinal chemistry.. 2009 December 1052 (23):7389-96. Epub 1900 01 01.

Syntheses of novel high affinity ligands for opioid receptors.

Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, Ganorkar R, VanAlstine MA, Guo C, Cohen DJ, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2009 April 1519 (8):2289-94. Epub 02/25/2009.

Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants of cyclazocine.

Wentland MP, Lu Q, Ganorkar R, Zhang SZ, Jo S, Cohen DJ, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2009 January 1519 (2):365-8. Epub 11/24/2008.

Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.

Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2009 January 119 (1):203-8. Epub 11/07/2008.

Glycosyl-enkephalins: synthesis and binding at the mu, delta & kappa opioid receptors. Antinociception in mice.

Keyari CM, Knapp BI, Bidlack JM, Lowey J, Bilsky EJ, Polt R

Advances in experimental medicine and biology.. 2009 611 :495-6. Epub 1900 01 01.

A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence.

Mathews JL, Smrcka AV, Bidlack JM

The Journal of neuroscience : the official journal of the Society for Neuroscience.. 2008 November 1928 (47):12183-9. Epub 1900 01 01.

In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.

Mathews JL, Fulton BS, Negus SS, Neumeyer JL, Bidlack JM

Neurochemical research.. 2008 October 33 (10):2142-50. Epub 06/05/2008.

Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.

Fulton BS, Knapp BI, Bidlack JM, Neumeyer JL

Bioorganic & medicinal chemistry letters.. 2008 August 1518 (16):4474-6. Epub 07/17/2008.

Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine.

Wentland MP, Sun X, Cohen DJ, Bidlack JM

Bioorganic & medicinal chemistry.. 2008 May 1516 (10):5653-64. Epub 03/30/2008.

Extracellular biotransformation of beta-endorphin in rat striatum and cerebrospinal fluid.

Reed B, Bidlack JM, Chait BT, Kreek MJ

Journal of neuroendocrinology.. 2008 May 20 (5):606-16. Epub 03/15/2008.

Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC.

VanAlstine MA, Wentland MP, Cohen DJ, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2007 December 117 (23):6516-20. Epub 09/29/2007.

In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.

Peng X, Knapp BI, Bidlack JM, Neumeyer JL

Bioorganic & medicinal chemistry.. 2007 June 1515 (12):4106-12. Epub 03/30/2007.

Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol.

Zhang A, Li F, Ding C, Yao Q, Knapp BI, Bidlack JM, Neumeyer JL

Journal of medicinal chemistry.. 2007 May 3150 (11):2747-51. Epub 05/09/2007.

Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.

Peng X, Knapp BI, Bidlack JM, Neumeyer JL

Journal of medicinal chemistry.. 2007 May 350 (9):2254-8. Epub 04/04/2007.

High-affinity carbamate analogues of morphinan at opioid receptors.

Peng X, Knapp BI, Bidlack JM, Neumeyer JL

Bioorganic & medicinal chemistry letters.. 2007 March 1517 (6):1508-11. Epub 01/17/2007.

Glycosylation improves the central effects of DAMGO.

Lowery JJ, Yeomans L, Keyari CM, Davis P, Porreca F, Knapp BI, Bidlack JM, Bilsky EJ, Polt R

Chemical biology & drug design.. 2007 January 69 (1):41-7. Epub 1900 01 01.

Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine.

Wentland MP, VanAlstine M, Kucejko R, Lou R, Cohen DJ, Parkhill AL, Bidlack JM

Journal of medicinal chemistry.. 2006 September 749 (18):5635-9. Epub 1900 01 01.

New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.

Neumeyer JL, Peng X, Knapp BI, Bidlack JM, Lazarus LH, Salvadori S, Trapella C, Balboni G

Journal of medicinal chemistry.. 2006 September 749 (18):5640-3. Epub 1900 01 01.

Opioid receptors and signaling on cells from the immune system.

Bidlack JM, Khimich M, Parkhill AL, Sumagin S, Sun B, Tipton CM

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.. 2006 September 1 (3):260-9. Epub 07/08/2006.

Identification of potent and highly selective chiral tri-amine and tetra-amine mu opioid receptors ligands: an example of lead optimization using mixture-based libraries.

Nefzi A, Ostresh JM, Appel JR, Bidlack J, Dooley CT, Houghten RA

Bioorganic & medicinal chemistry letters.. 2006 August 1516 (16):4331-8. Epub 06/05/2006.

Reduction of lipopolysaccharide-induced interleukin-6 production by the kappa opioid U50,488 in a mouse monocyte-like cell line.

Parkhill AL, Bidlack JM

International immunopharmacology.. 2006 June 6 (6):1013-9. Epub 02/17/2006.

The expression of prodynorphin gene is down-regulated by activation with lipopolysaccharide in U-937 macrophage cells.

Sun B, Tipton CM, Bidlack JM

Journal of neuroimmunology.. 2006 May 174 (1-2):52-62. Epub 02/17/2006.

Differential targeting of Gbetagamma-subunit signaling with small molecules.

Bonacci TM, Mathews JL, Yuan C, Lehmann DM, Malik S, Wu D, Font JL, Bidlack JM, Smrcka AV

Science.. 2006 April 21312 (5772):443-6. Epub 1900 01 01.

Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.

Peng X, Knapp BI, Bidlack JM, Neumeyer JL

Journal of medicinal chemistry.. 2006 January 1249 (1):256-62. Epub 1900 01 01.

Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?

Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.. 2005 December 30 (12):2254-62. Epub 1900 01 01.

Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.

Mathews JL, Peng X, Xiong W, Zhang A, Negus SS, Neumeyer JL, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 2005 November 315 (2):821-7. Epub 08/02/2005.

The human herpesvirus 6 G protein-coupled receptor homolog U51 positively regulates virus replication and enhances cell-cell fusion in vitro.

Zhen Z, Bradel-Tretheway B, Sumagin S, Bidlack JM, Dewhurst S

Journal of virology.. 2005 September 79 (18):11914-24. Epub 1900 01 01.

Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 3: 8-Thiocarboxamido and 8-thioformamido derivatives of cyclazocine.

Wentland MP, Sun X, Bu Y, Lou R, Cohen DJ, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2005 May 1615 (10):2547-51. Epub 1900 01 01.

Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone.

Wentland MP, Lu Q, Lou R, Bu Y, Knapp BI, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2005 April 1515 (8):2107-10. Epub 1900 01 01.

Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys.

Stevenson GW, Wentland MP, Bidlack JM, Mello NK, Negus SS

European journal of pharmacology.. 2004 December 15506 (2):133-41. Epub 1900 01 01.

Transient overexpression of kappa and mu opioid receptors using recombinant adenovirus vectors.

Zhen Z, Bradel-Tretheway BG, Dewhurst S, Bidlack JM

Journal of neuroscience methods.. 2004 July 30136 (2):133-9. Epub 1900 01 01.

An investigation of the N-demethylation of 3-deoxymorphine and the affinity of the alkylation products to mu, delta, and kappa receptors.

Csutoras C, Zhang A, Bidlack JM, Neumeyer JL

Bioorganic & medicinal chemistry.. 2004 May 1512 (10):2687-90. Epub 1900 01 01.

Kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells.

Gekker G, Hu S, Wentland MP, Bidlack JM, Lokensgard JR, Peterson PK

The Journal of pharmacology and experimental therapeutics.. 2004 May 309 (2):600-6. Epub 02/02/2004.

2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.

Zhang A, Xiong W, Hilbert JE, DeVita EK, Bidlack JM, Neumeyer JL

Journal of medicinal chemistry.. 2004 April 847 (8):1886-8. Epub 1900 01 01.

Kappa-opioid receptors are differentially labeled by arylacetamides and benzomorphans.

Rusovici DE, Negus SS, Mello NK, Bidlack JM

European journal of pharmacology.. 2004 February 6485 (1-3):119-25. Epub 1900 01 01.

10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.

Zhang A, Xiong W, Bidlack JM, Hilbert JE, Knapp BI, Wentland MP, Neumeyer JL

Journal of medicinal chemistry.. 2004 January 147 (1):165-74. Epub 1900 01 01.

Assay of G protein-coupled receptor activation of G proteins in native cell membranes using [35S]GTP gamma S binding.

Bidlack JM, Parkhill AL

Methods in molecular biology.. 2004 237 :135-43. Epub 1900 01 01.

Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.

Neumeyer JL, Zhang A, Xiong W, Gu XH, Hilbert JE, Knapp BI, Negus SS, Mello NK, Bidlack JM

Journal of medicinal chemistry.. 2003 November 2046 (24):5162-70. Epub 1900 01 01.

Synthesis and pharmacology of 8-amino-3-[(tetrahydro-2-furanyl)methyl] benzomorphan.

Zhou Q, Duan WH, Cohen DJ, Bidlack JM, Wentland MP

Yao xue xue bao = Acta pharmaceutica Sinica.. 2003 October 38 (10):748-53. Epub 1900 01 01.

Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents.

Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, Glick SD, Bidlack JM

Journal of medicinal chemistry.. 2003 June 1946 (13):2716-30. Epub 1900 01 01.

Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 2: 8-formamidocyclazocine analogues.

Wentland MP, Sun X, Ye Y, Lou R, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2003 June 213 (11):1911-4. Epub 1900 01 01.

Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys.

Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, Mello NK

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.. 2003 June 28 (6):1125-39. Epub 03/05/2003.

Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines.

Wentland MP, Ye Y, Cioffi CL, Lou R, Zhou Q, Xu G, Duan W, Dehnhardt CM, Sun X, Cohen DJ, Bidlack JM

Journal of medicinal chemistry.. 2003 February 2746 (5):838-49. Epub 1900 01 01.

Delta opioid antagonist effects of buprenorphine in rhesus monkeys.

Negus SS, Bidlack JM, Mello NK, Furness MS, Rice KC, Brandt MR

Behavioural pharmacology.. 2002 November 13 (7):557-70. Epub 1900 01 01.

Several delta-opioid receptor ligands display no subtype selectivity to the human delta-opioid receptor.

Parkhill AL, Bidlack JM

European journal of pharmacology.. 2002 September 20451 (3):257-64. Epub 1900 01 01.

8-Carboxamidocyclazocine: a long-acting, novel benzomorphan.

Bidlack JM, Cohen DJ, McLaughlin JP, Lou R, Ye Y, Wentland MP

The Journal of pharmacology and experimental therapeutics.. 2002 July 302 (1):374-80. Epub 1900 01 01.

Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.

Neumeyer JL, Gu XH, van Vliet LA, DeNunzio NJ, Rusovici DE, Cohen DJ, Negus SS, Mello NK, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2001 October 2211 (20):2735-40. Epub 1900 01 01.

Kappa-opioid receptors on lymphocytes of a human lymphocytic cell line: morphine-induced up-regulation as evidenced by competitive RT-PCR and indirect immunofluorescence.

Suzuki S, Chuang LF, Doi RH, Bidlack JM, Chuang RY

International immunopharmacology.. 2001 September 1 (9-10):1733-42. Epub 1900 01 01.

3-Carboxamido analogues of morphine and naltrexone. synthesis and opioid receptor binding properties.

Wentland MP, Lou R, Dehnhardt CM, Duan W, Cohen DJ, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2001 July 911 (13):1717-21. Epub 1900 01 01.

Kappa-opioid receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes.

Peterson PK, Gekker G, Lokensgard JR, Bidlack JM, Chang AC, Fang X, Portoghese PS

Biochemical pharmacology.. 2001 May 161 (9):1145-51. Epub 1900 01 01.

8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2,6-methano-3-benzazocines.

Wentland MP, Lou R, Ye Y, Cohen DJ, Richardson GP, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2001 March 1211 (5):623-6. Epub 1900 01 01.

Mitogen-induced activation of mouse T cells increases kappa opioid receptor expression.

Bidlack JM, Abraham MK

Advances in experimental medicine and biology.. 2001 493 :103-10. Epub 1900 01 01.

Selective protection and functionalization of morphine: synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives.

Wentland MP, Duan W, Cohen DJ, Bidlack JM

Journal of medicinal chemistry.. 2000 September 2143 (19):3558-65. Epub 1900 01 01.

Detection and function of opioid receptors on cells from the immune system.

Bidlack JM

Clinical and diagnostic laboratory immunology.. 2000 September 7 (5):719-23. Epub 1900 01 01.

Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse.

Neumeyer JL, Mello NK, Negus SS, Bidlack JM

Pharmaceutica acta Helvetiae. 2000 March 74 (2-3):337-44. Epub 1900 01 01.

8-Aminocyclazocine analogues: synthesis and structure-activity relationships.

Wentland MP, Xu G, Cioffi CL, Ye Y, Duan W, Cohen DJ, Colasurdo AM, Bidlack JM

Bioorganic & medicinal chemistry letters.. 2000 January 1710 (2):183-7. Epub 1900 01 01.

Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.

Neumeyer JL, Bidlack JM, Zong R, Bakthavachalam V, Gao P, Cohen DJ, Negus SS, Mello NK

Journal of medicinal chemistry.. 2000 January 1343 (1):114-22. Epub 1900 01 01.

Partial opioids. Medications for the treatment of pain and drug abuse.

Bidlack JM, McLaughlin JP, Wentland MP

Annals of the New York Academy of Sciences.. 2000 909 :1-11. Epub 1900 01 01.

Pharmacological profiles of kappa opioids. Correlation between [35S]GTP gamma S binding and cyclic AMP production.

Bidlack JM, Jadrovski I

Annals of the New York Academy of Sciences.. 2000 909 :264. Epub 1900 01 01.

Genetic alteration of phospholipase C beta3 expression modulates behavioral and cellular responses to mu opioids.

Xie W, Samoriski GM, McLaughlin JP, Romoser VA, Smrcka A, Hinkle PM, Bidlack JM, Gross RA, Jiang H, Wu D

Proceedings of the National Academy of Sciences of the United States of America.. 1999 August 3196 (18):10385-90. Epub 1900 01 01.

Differential kappa-opioid receptor expression on mouse lymphocytes at varying stages of maturation and on mouse macrophages after selective elicitation.

Ignatowski TA, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1999 August 290 (2):863-70. Epub 1900 01 01.

Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.

McLaughlin JP, Hill KP, Jiang Q, Sebastian A, Archer S, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1999 April 289 (1):304-11. Epub 1900 01 01.

The synthetic kappa-opioid agonist (-)U50,488 does not affect calcium transport into R1.1 mouse thymoma cell line.

Martin-Kleiner I, Bidlack JM

International journal of immunopharmacology.. 1999 February 21 (2):133-40. Epub 1900 01 01.

Selective ligands for the mu, delta, and kappa opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library.

Dooley CT, Ny P, Bidlack JM, Houghten RA

The Journal of biological chemistry.. 1998 July 24273 (30):18848-56. Epub 1900 01 01.

Evidence for opioid receptors on cells involved in host defense and the immune system.

Sharp BM, Roy S, Bidlack JM

Journal of neuroimmunology.. 1998 March 1583 (1-2):45-56. Epub 1900 01 01.

The nitric oxide/cyclic GMP system at the supraspinal site is involved in the development of acute morphine antinociceptive tolerance.

Xu JY, Hill KP, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1998 January 284 (1):196-201. Epub 1900 01 01.

Detection of kappa opioid receptors on mouse thymocyte phenotypic subpopulations as assessed by flow cytometry.

Ignatowski TA, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1998 January 284 (1):298-306. Epub 1900 01 01.

Changes in kappa opioid receptor expression during maturation of mouse lymphocytes.

Ignatowski TA, Bidlack JM

Advances in experimental medicine and biology.. 1998 437 :117-24. Epub 1900 01 01.

Fluorescent staining of kappa opioid receptors using naltrexamine derivatives and phycoerythrin.

Lawrence DM, Hutchinson I, Seyed-Mozaffari A, Archer S, Bidlack JM

Journal of immunological methods.. 1997 February 28201 (2):173-81. Epub 1900 01 01.

14 beta-Chlorocinnamoylamino derivatives of metopon: long-term mu-opioid receptor antagonists.

McLaughlin JP, Sebastian A, Archer S, Bidlack JM

European journal of pharmacology.. 1997 February 12320 (2-3):121-9. Epub 1900 01 01.

N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.

Xu JY, Seyed-Mozaffari A, Archer S, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1996 November 279 (2):539-47. Epub 1900 01 01.

Cyclazocine revisited.

Archer S, Glick SD, Bidlack JM

Neurochemical research.. 1996 November 21 (11):1369-73. Epub 1900 01 01.

Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys.

Gatch MB, Negus SS, Mello NK, Archer S, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1996 September 278 (3):1282-9. Epub 1900 01 01.

kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression.

Chao CC, Gekker G, Hu S, Sheng WS, Shark KB, Bu DF, Archer S, Bidlack JM, Peterson PK

Proceedings of the National Academy of Sciences of the United States of America.. 1996 July 2393 (15):8051-6. Epub 1900 01 01.

Asymmetric syntheses, opioid receptor affinities, and antinociceptive effects of 8-amino-5,9-methanobenzocyclooctenes, a new class of structural analogues of the morphine alkaloids.

Schultz AG, Wang A, Alva C, Sebastian A, Glick SD, Deecher DC, Bidlack JM

Journal of medicinal chemistry.. 1996 May 1039 (10):1956-66. Epub 1900 01 01.

Kappa Opioid receptors on immune cells as studied by fluorescent ligands.

Bidlack JM, Lawrence DM, Ignatowski TA

Advances in experimental medicine and biology.. 1996 402 :13-22. Epub 1900 01 01.

Molecular and biochemical evidence for receptors for drugs of abuse on immune cells.

Liu-Chen LY, Bidlack JM, Rogers TJ, Klein TW, Madden JJ, Sharp BM, Evans CJ

NIDA research monograph.. 1996 162 :37-9. Epub 1900 01 01.

Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors.

McLaughlin JP, Nowak D, Sebastian A, Schultz AG, Archer S, Bidlack JM

European journal of pharmacology.. 1995 December 27294 (1):201-6. Epub 1900 01 01.

Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.

Jiang Q, Seyed-Mozaffari A, Sebastian A, Archer S, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1995 May 273 (2):680-8. Epub 1900 01 01.

The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line down-regulates without desensitizing during chronic opioid exposure.

Joseph DB, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1995 March 272 (3):970-6. Epub 1900 01 01.

Identification of kappa opioid receptors in the immune system by indirect immunofluorescence.

Lawrence DM, el-Hamouly W, Archer S, Leary JF, Bidlack JM

Proceedings of the National Academy of Sciences of the United States of America.. 1995 February 1492 (4):1062-6. Epub 1900 01 01.

Kappa opioid receptors expressed on three related thymoma cell lines. Differences in receptor-effector coupling.

Lawrence DM, Joseph DB, Bidlack JM

Biochemical pharmacology.. 1995 January 649 (1):81-9. Epub 1900 01 01.

Identification of opioid receptors in the immune system using a novel combination of selective opioid ligands and indirect phycoerythrin immunofluorescence.

Lawrence DM, Archer S, Bidlack JM

Advances in experimental medicine and biology.. 1995 373 :17-21. Epub 1900 01 01.

Kappa opioid receptors on three related thymoma cell lines. Differences in receptor-effector coupling.

Bidlack JM, Joseph DB, Lawrence DM

Advances in experimental medicine and biology.. 1995 373 :23-7. Epub 1900 01 01.

Six highly active mu-selective opioid peptides identified from two synthetic combinatorial libraries.

Dooley CT, Kaplan RA, Chung NN, Schiller PW, Bidlack JM, Houghten RA

Peptide research. 1995 8 (3):124-37. Epub 1900 01 01.

An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library.

Dooley CT, Chung NN, Wilkes BC, Schiller PW, Bidlack JM, Pasternak GW, Houghten RA

Science.. 1994 December 23266 (5193):2019-22. Epub 1900 01 01.

The kappa-opioid receptor expressed on the mouse lymphoma cell line R1.1 contains a sulfhydryl group at the binding site.

Joseph DB, Bidlack JM

European journal of pharmacology.. 1994 March 15267 (1):1-6. Epub 1900 01 01.

14 beta-[(p-nitrocinnamoyl)amino]morphinones, 14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinones, and their codeinone analogues: synthesis and receptor activity.

Sebastian A, Bidlack JM, Jiang Q, Deecher D, Teitler M, Glick SD, Archer S

Journal of medicinal chemistry.. 1993 October 1536 (21):3154-60. Epub 1900 01 01.

The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein.

Lawrence DM, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1993 September 266 (3):1678-83. Epub 1900 01 01.

Antinociceptive evaluation of 14 beta-(bromoacetamido)-7,8-dihydro- N(cyclopropylmethyl)-normorphinone in mice.

Jiang Q, Seyed-Mozaffari A, Archer S, Bidlack JM

European journal of pharmacology.. 1993 August 24240 (2-3):201-6. Epub 1900 01 01.

Affinity labeling of the mu opioid receptor in bovine striatal membranes with [3H]-14 beta-(bromoacetamido)-7,8-dihydromorphine.

Bidlack JM, Kaplan RA, Subbramanian RA, Seyed-Mozaffari A, Archer S

Biochemistry.. 1993 July 632 (26):6703-11. Epub 1900 01 01.

Pharmacological study of 14 beta-(thioglycolamido)-7,8-dihydro-N(cyclopropylmethyl)-normor phinone (N-CPM-TAMO).

Jiang Q, Seyed-Mozaffari A, Archer S, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1993 March 264 (3):1021-7. Epub 1900 01 01.

5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: a long-lasting mu-opioid receptor antagonist devoid of agonist properties.

Jiang Q, Sebastian A, Archer S, Bidlack JM

European journal of pharmacology.. 1993 January 5230 (1):129-30. Epub 1900 01 01.

Kappa opioid binding sites on the R1.1 murine lymphoma cell line: sensitivity to cations and guanine nucleotides.

Lawrence DM, Bidlack JM

Journal of neuroimmunology.. 1992 December 41 (2):223-30. Epub 1900 01 01.

kappa-Opioid binding sites on a murine lymphoma cell line.

Bidlack JM, Saripalli LD, Lawrence DM

European journal of pharmacology.. 1992 November 2227 (3):257-65. Epub 1900 01 01.

Effects of beta-endorphin on mu and delta opioid receptor-coupled G-protein activity: low-Km GTPase studies.

Selley DE, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1992 October 263 (1):99-104. Epub 1900 01 01.

Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO).

Jiang Q, Seyed-Mozaffari A, Archer S, Bidlack JM

The Journal of pharmacology and experimental therapeutics.. 1992 August 262 (2):526-31. Epub 1900 01 01.

Endorphin peptides enhance mitogen-induced T cell proliferation which has been suppressed by prostaglandins.

Hemmick LM, Bidlack JM

Advances in experimental medicine and biology.. 1991 288 :211-4. Epub 1900 01 01.

Purification, cloning, and tissue distribution of a 23-kDa rat protein isolated by morphine affinity chromatography.

Grandy DK, Hanneman E, Bunzow J, Shih M, Machida CA, Bidlack JM, Civelli O

Molecular endocrinology.. 1990 September 4 (9):1370-6. Epub 1900 01 01.

Affinity labeling of mu opioid receptors by sulfhydryl alkylating derivatives of morphine and morphinone.

Bidlack JM, Frey DK, Kaplan RA, Seyed-Mozaffari A, Archer S

Molecular pharmacology.. 1990 January 37 (1):50-9. Epub 1900 01 01.

Morphine enhancement of mitogen-induced T-cell proliferation.

Bidlack JM, Hemmick LM

Progress in clinical and biological research.. 1990 328 :405-8. Epub 1900 01 01.

Beta-endorphin stimulates rat T lymphocyte proliferation.

Hemmick LM, Bidlack JM

Journal of neuroimmunology.. 1990 29 (1-3):239-48. Epub 1900 01 01.

Beta-endorphin suppresses rat plaque-forming cell response by a non-opioid mechanism.

Hemmick LM, Bidlack JM

Journal of neuroimmunology.. 1989 June 23 (1):67-71. Epub 1900 01 01.

14 beta-(Bromoacetamido)morphine irreversibly labels mu opioid receptors in rat brain membranes.

Bidlack JM, Frey DK, Seyed-Mozaffari A, Archer S

Biochemistry.. 1989 May 1628 (10):4333-9. Epub 1900 01 01.

Irreversible affinity ligands for mu opioid receptors.

Bidlack JM, Frey DK, Seyed-Mozaffari A, Archer S

NIDA research monograph.. 1989 95 :296. Epub 1900 01 01.

Cation requirement for GTP regulation of [125I]b-endorphin binding to Mu and sigma opioid receptors.

Selley DE, Bidlack JM

NIDA research monograph.. 1989 95 :537-8. Epub 1900 01 01.

Guanine nucleotide regulation of [125I]beta-endorphin binding to rat brain membranes: monovalent cation requirement.

Selley DE, Tyler CB, Bidlack JM

Journal of neurochemistry.. 1988 June 50 (6):1844-50. Epub 1900 01 01.

Comparison of [125I]beta-endorphin binding to rat brain and NG108-15 cells using a monoclonal antibody directed against the opioid receptor.

Bidlack JM, O'Malley WE, Schulz R

Molecular pharmacology.. 1988 February 33 (2):170-7. Epub 1900 01 01.

Beta-endorphin modulation of mitogen-stimulated calcium uptake by rat thymocytes.

Hemmick LM, Bidlack JM

Life sciences.. 1987 October 1941 (16):1971-8. Epub 1900 01 01.

Inhibition of mu and delta but not kappa opioid binding to membranes by Fab fragments from a monoclonal antibody directed against the opioid receptor.

Bidlack JM, O'Malley WE

The Journal of biological chemistry.. 1986 December 5261 (34):15844-9. Epub 1900 01 01.

Preparation of Fab fragments from a mouse monoclonal IgM.

Bidlack JM, Mabie PC

Journal of immunological methods.. 1986 July 2491 (2):157-62. Epub 1900 01 01.

Free kappa light chains in multiple sclerosis spinal fluid.

Rudick RA, Pallant A, Bidlack JM, Herndon RM

Annals of neurology.. 1986 July 20 (1):63-9. Epub 1900 01 01.

A monoclonal antibody capable of modulating opioid binding to rat neural membranes.

Bidlack JM, Denton RR

The Journal of biological chemistry.. 1985 December 15260 (29):15655-61. Epub 1900 01 01.

Multiple sclerosis: free light chains in cerebrospinal fluid.

Rudick RA, Peter DR, Bidlack JM, Knutson DW

Neurology.. 1985 October 35 (10):1443-9. Epub 1900 01 01.

Multiple sclerosis. Cerebrospinal fluid immune complexes that bind C1q.

Rudick RA, Bidlack JM, Knutson DW

Archives of neurology.. 1985 September 42 (9):856-8. Epub 1900 01 01.

A monoclonal antibody directed against an opiate binding site in rat neural membranes.

Bidlack JM, Denton RR

Neuropeptides.. 1984 December 5 (1-3):225-8. Epub 1900 01 01.

A freezing method for cell fusions to distribute and reduce labor and permit more thorough early evaluation of hybridomas.

Harwell LW, Bolognino M, Bidlack JM, Knapp RJ, Lord EM

Journal of immunological methods.. 1984 January 2066 (1):59-67. Epub 1900 01 01.

14 beta-(2-bromoacetamido)morphine and 14 beta-(2-bromoacetamido)morphinone.

Archer S, Seyed-Mozaffari A, Osei-Gyimah P, Bidlack JM, Abood LG

Journal of medicinal chemistry.. 1983 December 26 (12):1775-7. Epub 1900 01 01.

Molecular characteristics of brain opiate and nicotine receptors.

Bidlack JM, Abood LG

Biomembranes. 1983 11 :415-37. Epub 1900 01 01.

Generating monoclonal antibodies to the opioid receptor.

Bidlack JM, Denton RR, Harwell LW

Life sciences.. 1983 33 Suppl 1 :151-4. Epub 1900 01 01.

Purification of phospholamban, a 22,000-dalton protein from cardiac sarcoplasmic reticulum that is specifically phosphorylated by cyclic AMP-dependent protein kinase.

Bidlack JM, Ambudkar IS, Shamoo AE

The Journal of biological chemistry.. 1982 April 25257 (8):4501-6. Epub 1900 01 01.

Affinity labeling and purification of the opiate receptor from rat brain.

Bidlack JM, Abood LG, Munemitsu SM, Archer S, Gala D, Kreilick RW

Advances in biochemical psychopharmacology.. 1982 33 :301-9. Epub 1900 01 01.

Purification of the opiate receptor from rat brain.

Bidlack JM, Abood LG, Osei-Gyimah P, Archer S

Proceedings of the National Academy of Sciences of the United States of America.. 1981 January 78 (1):636-9. Epub 1900 01 01.

Sites and mechanisms for nicotine's action in the brain.

Abood LG, Reynolds DT, Booth H, Bidlack JM

Neuroscience and biobehavioral reviews.. 1981 5 (4):479-86. Epub 1900 01 01.

Stereospecific 3H-nicotine binding to intact and solubilized rat brain membranes and evidence for its noncholinergic nature.

Abood LG, Reynolds DT, Bidlack JM

Life sciences.. 1980 October 627 (14):1307-14. Epub 1900 01 01.

Adenosine 3',5'-monophosphate-dependent phosphorylation of a 6000 and a 22,000 dalton protein from cardiac sarcoplasmic reticulum.

Bidlack JM, Shamoo AE

Biochimica et biophysica acta.. 1980 October 1632 (2):310-25. Epub 1900 01 01.

Solubilization of the opiate receptor.

Bidlack JM, Abood LG

Life sciences.. 1980 July 2827 (4):331-40. Epub 1900 01 01.

Evolution of LDH isozymes during programmed cell death.

Bidlack JM, Lockshin RA

Comparative biochemistry and physiology. B, Comparative biochemistry.. 1976 55 (2):161-6. Epub 1900 01 01.

Books

Opiate Receptors and Antagonists: From Bench to Clinic (2009)

Chapter: The Chemistry and Pharmacology of Mu Opioid Antagonists

Authors: Bidlack, J.M., and Mathews, J.L.

Publisher: Humana Press, Totowa, NJ 2009

Phi Kappa Phi Forum (2007)

Chapter: Review of Carleton K. Erickson. The Science of Addiction: From Neurobiology to Treatment.

Authors: Bidlack, JM

Publisher: W.W. Norton & Company, New York 2007